- Trials with a EudraCT protocol (140)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
140 result(s) found for: Eye Diseases AND Retinal Degeneration AND Retinal Diseases.
Displaying page 1 of 7.
| EudraCT Number: 2019-002821-31 | Sponsor Protocol Number: AKST4290-206 | Start Date*: 2019-10-10 | |||||||||||
| Sponsor Name:Alkahest, Inc | |||||||||||||
| Full Title: The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
| Medical condition: Age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003352-20 | Sponsor Protocol Number: 469055 | Start Date*: 2016-07-18 | |||||||||||
| Sponsor Name:University Medical Center of Johannes -Gutenberg University Mainz | |||||||||||||
| Full Title: Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospec... | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration (AMD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002168-34 | Sponsor Protocol Number: FNB-OK-2013-01 | Start Date*: 2014-12-09 | |||||||||||||||||||||
| Sponsor Name:Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno | |||||||||||||||||||||||
| Full Title: Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration | |||||||||||||||||||||||
| Medical condition: Retinal angiomatous proliferation secondary to wet age related macular degeneration. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-001085-10 | Sponsor Protocol Number: CRFB002AGB17 | Start Date*: 2014-09-08 | |||||||||||
| Sponsor Name:Novartis Pharmaceuticals UK Ltd | |||||||||||||
| Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit... | |||||||||||||
| Medical condition: Visual impairment due to neovascular AMD | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001961-20 | Sponsor Protocol Number: FYB201-C2015-01-P3 | Start Date*: 2015-11-24 | ||||||||||||||||
| Sponsor Name:Bioeq GmbH | ||||||||||||||||||
| Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD) | ||||||||||||||||||
| Medical condition: Subfoveal neovascular age-related macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-001058-73 | Sponsor Protocol Number: BEY-RAP.V1.0 | Start Date*: 2021-06-23 |
| Sponsor Name:Fakultní nemocnice Královské Vinohrady | ||
| Full Title: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study | ||
| Medical condition: Retinal angiomatous proliferation form of neovascular age related macular degeneration (AMD). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002698-20 | Sponsor Protocol Number: OPT-302-1002 | Start Date*: 2018-02-07 | |||||||||||||||||||||
| Sponsor Name:Opthea Ltd | |||||||||||||||||||||||
| Full Title: A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD) | |||||||||||||||||||||||
| Medical condition: Neovascular age-related macular degeneration (wet AMD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) LV (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-004567-30 | Sponsor Protocol Number: 1313.20 | Start Date*: 2014-04-15 | |||||||||||
| Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
| Full Title: A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD) | |||||||||||||
| Medical condition: patients with newly diagnosed, unilateral, wet Are-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000103-27 | Sponsor Protocol Number: Eylea-2014 | Start Date*: 2014-03-12 |
| Sponsor Name: | ||
| Full Title: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration. | ||
| Medical condition: Exudative age-related macular degeneration (AMD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-000946-37 | Sponsor Protocol Number: 2019-06 | Start Date*: 2020-11-30 | |||||||||||
| Sponsor Name:Assistance Publique-Hôpitaux de Marseille | |||||||||||||
| Full Title: Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients. | |||||||||||||
| Medical condition: Age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-021968-15 | Sponsor Protocol Number: ID_2909 | Start Date*: 2010-08-06 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
| Full Title: NOT RANDOMISED OPEN LABEL STUDY TO COMPARE EFFICACY OF BEVACIZUMAB (AVASTIN, ROCHE) VERSUS RANIBIZUMAB (LUCENTIS, NOVARTIS) ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH EXUDATIVE AGE REL... | |||||||||||||
| Medical condition: exudative age related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001061-37 | Sponsor Protocol Number: KS301P103 | Start Date*: 2020-12-11 | |||||||||||||||||||||||||||||||
| Sponsor Name:Kodiak Sciences Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A... | |||||||||||||||||||||||||||||||||
| Medical condition: Macular edema secondary to retinal vein occlusion | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: LV (Prematurely Ended) DE (Completed) SK (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-001492-37 | Sponsor Protocol Number: Z-AMD | Start Date*: 2019-11-01 | |||||||||||
| Sponsor Name:Oslo University Hospital | |||||||||||||
| Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study | |||||||||||||
| Medical condition: Neovascular Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004736-24 | Sponsor Protocol Number: OPT-302-1004 | Start Date*: 2021-07-19 | |||||||||||||||||||||
| Sponsor Name:Opthea Limited | |||||||||||||||||||||||
| Full Title: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants... | |||||||||||||||||||||||
| Medical condition: Neovascular age-related macular degeneration (wet AMD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) BG (Completed) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2008-004844-35 | Sponsor Protocol Number: TG-MV-005 | Start Date*: 2009-07-01 | |||||||||||||||||||||
| Sponsor Name:ThromboGenics NV | |||||||||||||||||||||||
| Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD). | |||||||||||||||||||||||
| Medical condition: Patients with exudative AMD with focal vitreomacular adhesion | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-004694-46 | Sponsor Protocol Number: OPT-302-1005 | Start Date*: 2021-08-06 | |||||||||||||||||||||
| Sponsor Name:Opthea Limited | |||||||||||||||||||||||
| Full Title: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants... | |||||||||||||||||||||||
| Medical condition: Neovascular Age-related Macular Degeneration (wet AMD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) DK (Completed) FR (Trial now transitioned) LV (Trial now transitioned) EE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-002526-43 | Sponsor Protocol Number: 150998-001 | Start Date*: 2012-01-30 | |||||||||||
| Sponsor Name:Allergan Limited | |||||||||||||
| Full Title: Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration | |||||||||||||
| Medical condition: Exudative Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003763-22 | Sponsor Protocol Number: BAY73-4506/15984 | Start Date*: 2014-07-02 | ||||||||||||||||||||||||||
| Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||||||||||||
| Full Title: A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degen... | ||||||||||||||||||||||||||||
| Medical condition: neovascular age related macular degeneration | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-021923-29 | Sponsor Protocol Number: 10032011 | Start Date*: 2011-08-11 | |||||||||||
| Sponsor Name:Universitätsklinik für Augenheilkunden und Optometrie, Medizinische Universität Wien | |||||||||||||
| Full Title: Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration A prospective, randomized, clinical study | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-000133-12 | Sponsor Protocol Number: SBR-ITA13 | Start Date*: 2013-07-20 |
| Sponsor Name:Azienda Ospedaliera Universitaria Integrata Verona | ||
| Full Title: A randomized controlled multicentre open-label parallel arm study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab (allocation 4:1) administered by intravitreal in... | ||
| Medical condition: - Age-related macular degeneration - Diabetic retinal oedema - Retinal perivascular sheathing - Choroidal neovascularisation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
